Stock Report

Download full stock data and analysis for free Last Updated: 29-Aug-2026

Stock Rating

Is this stock worth it? Our ratings reveal the truth.

Wealth Insight New Issue

This month’s issue could change how you invest, read now.

Recently Viewed

Clear All

Rubra Medicaments Key Ratios

Stock Card factsheet watchlist-stock-modal share-fund-plan-icon

BSE: 531099

₹36.79

up-down-arrow ₹-1.22 (-3.21%)

As on 28-Aug-2026IST

Market cap

info icon

₹20 Cr

Revenue (TTM)

info icon

₹562 Cr

P/E Ratio

info icon

16.3

P/B Ratio

info icon

10.7

Div. Yield

info icon

0 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue -- -- 4,540.45 771.23 243.17
EBIT 50.40 -304.44 1,710.81 144.20 144.51
Net Profit 61.51 -304.44 1,322.32 117.15 133.00
EPS 61.51 -304.43 1,288.45 117.93 133.02
Book Value -- -- 4.77 31.84 15.25
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMMar-25Mar-24
EBIT-Margin info 1.831.210.3610.282.29
Net Margin info 0.330.060.225.072.67
Return on equity info -8.38-7.419.814.668.66
Return on Capital info 0.36-0.25--9.644.53
Return on Assets info -1.13-1.380.723.223.81
Debt to Equity (x) info ----0.000.000.00

Profitability

View Detailed Peer Comparison

ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Rubra Medicaments
--
9.64
4.53
-13.10
-3.70
Peer Median
--
3.84
5.02
9.20
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

9.81

Higher than Peers by 8.28

Profit after tax / Average Net worth * 100

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Rubra Medicaments
9.81
4.66
8.66
-38.44
-13.95
Peer Median
1.53
5.08
1.59
9.09
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

0.72

Lower than Peers by 0.06

Profit after tax / Average Total assets * 100

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Rubra Medicaments
0.72
3.22
3.81
-10.43
-4.17
Peer Median
0.78
2.19
1.46
2.77
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

0.36

Higher than Peers by 9.19

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Rubra Medicaments
0.36
10.28
2.29
-7.09
-1.14
Peer Median
-8.83
2.93
3.78
4.14
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

0.22

Lower than Peers by 1.90

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Rubra Medicaments
0.22
5.07
2.67
-6.76
-1.82
Peer Median
2.12
1.96
3.27
13.99
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Profit Margin

0.00

--

(Net profit + Depreciation) / Gross Sales * 100

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Rubra Medicaments
0.00
6.64
3.29
-6.52
-1.74
Peer Median
--
0.00
0.00
0.00
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Growth

View Detailed Peer Comparison

Revenue Growth

4,540.45

Higher than Peers by 4,546.12

Year on year growth in net sales

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Rubra Medicaments
4,540.45
-55.75
-2.60
-42.31
314.66
Peer Median
-5.67
50.75
56.32
1,43,500.00
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

1,710.81

Higher than Peers by 1,770.75

Year on year growth in operating profit (EBIT)

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Rubra Medicaments
1,710.81
98.46
131.50
-257.43
-374.74
Peer Median
-59.94
75.04
59.55
-70.24
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

1,322.32

Higher than Peers by 1,293.25

Year on year growth in profit after tax

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Rubra Medicaments
1,322.32
-15.89
138.45
-115.10
-750.74
Peer Median
29.07
39.96
-8.68
-48.33
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

1,288.45

Higher than Peers by 1,301.30

Year on year growth in earnings per share

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Rubra Medicaments
1,288.45
-15.94
138.44
-114.97
-748.54
Peer Median
-12.85
-21.00
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

--

--

Year on year growth in book value per share

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Rubra Medicaments
--
4.77
222.81
-32.25
-13.04
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Solvency

View Detailed Peer Comparison

Debt to Equity

--

--

Total debt / Net worth

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Rubra Medicaments
--
--
--
0.89
--
Peer Median
--
--
0.63
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

--

--

(Short term borrowings / Net worth)

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Rubra Medicaments
--
--
--
0.29
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

1.07

Lower than Peers by 12.99

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Rubra Medicaments
1.07
6.92
2.14
3.83
3.15
Peer Median
14.07
2.47
2.33
5.05
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

1.07

Lower than Peers by 12.05

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Rubra Medicaments
1.07
6.92
2.14
3.83
3.15
Peer Median
13.12
1.68
10.32
6.03
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

--

--

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Rubra Medicaments
--
10.12
6.09
-1,215.74
-195.28
Peer Median
7.62
2.66
2.65
2.05
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

60.08

Higher than Peers by 23.92

Debtors outstanding / Net Sales * 100

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Rubra Medicaments
60.08
57.00
62.59
37.09
33.13
Peer Median
36.16
15.37
42.99
49.21
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

3.27

Higher than Peers by 3.08

Sales / Average Total Assets

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Rubra Medicaments
3.27
0.63
1.43
1.54
2.30
Peer Median
0.19
1.51
1.33
0.50
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Rubra Medicaments
--
362.19
183.72
172.49
80.47
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Rubra Medicaments
--
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Rubra Medicaments
--
--
--
90.65
0.62
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Rubra Medicaments
--
--
--
81.84
79.85
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Valuation

View Detailed Peer Comparison

Price / Earnings

16.28

--

Current share price divided by earning per share in the last twelve months

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Rubra Medicaments
16.28
275.35
178.90
--
--
Peer Median
--
65.30
159.13
107.97
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Book Value

10.68

Higher than Peers by 10.39

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Rubra Medicaments
10.68
12.53
10.14
--
6.62
Peer Median
0.29
2.35
3.26
2.54
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

--

--

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Rubra Medicaments
--
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

13.28

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Rubra Medicaments
13.28
115.38
159.44
-71.89
-77.64
Peer Median
--
53.35
29.43
2.43
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

20

Lower than Peers by 11

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Rubra Medicaments
20
7
5
--
2
Peer Median
31
30
20
13
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...